Valvular & structural heart diseaseCohort study
Transcatheter Pulmonary Valve Replacement With Balloon-Expandable Valves
- Registry-based observational study
- multicentre registry
Authors' conclusion
This study describes novel population data on the use and procedural outcomes of TPVR with balloon-expandable valves. Over time, there has been increasing use of TPVR to treat regurgitant native RVOT anatomy, with the SAPIEN valve more commonly used for this application.
Study context
- Population
- Patients undergoing balloon-expandable transcatheter pulmonary valve replacement (TPVR), ACC NCDR IMPACT Registry, April 2016–March 2021
- Participants
- 4,513 TPVR procedures
Main finding
As reported in the abstract
Acute procedural success, by implant site
- Acute success, all patients
- 95%
Observational data: associations, not effects.
Further findings
Valve type and implant site
- Melody valve
- 57%
- SAPIEN valve
- 43%
- Homograft conduits
- One-third
- Bioprosthetic valves (BPVs)
- one-third
- Native or patched right ventricular outflow tracts (RVOTs)
- 25%
- Contegra conduits
- 6%
- SAPIEN use over study period
- ∼25% to 60%
- Most implanting centres performed <10 cases annually
- median age 19 years
Safety
Major adverse events
- Major adverse events — All procedures
- 2.4%
- Major adverse events: P = 0.004
Original publication
Transcatheter Pulmonary Valve Replacement With Balloon-Expandable Valves. JACC Cardiovasc Interv. Published 22 January 2024. doi:10.1016/j.jcin.2023.10.065
Summarised from the published abstract; every number is checked against it